Holen Sie sich die Stockscreener-App
192.62
1.39%
-2.72
Handel nachbörslich:
192.73
0.11
+0.06%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$195.34
Offen:
$197.25
24-Stunden-Volumen:
1.11M
Relative Volume:
0.97
Marktkapitalisierung:
$28.44B
Einnahmen:
$9.60B
Nettoeinkommen (Verlust:
$1.37B
KGV:
20.67
EPS:
9.3182
Netto-Cashflow:
$2.32B
1W Leistung:
+0.20%
1M Leistung:
-0.43%
6M Leistung:
+6.75%
1J Leistung:
+44.69%
1-Tages-Spanne:
$192.18
$198.69
1-Wochen-Bereich:
$184.90
$200.66
52-Wochen-Spanne:
$121.05
$205.97
Biogen Inc Stock (BIIB) Company Profile
Firmenname
Biogen Inc
Sektor
Telefon
(781) 464-2000
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB vs LLY, JNJ, ABBV, MRK, AZN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
192.62 | 28.84B | 9.60B | 1.37B | 2.32B | 9.3182 |
LLY
Lilly Eli Co
|
1,149.15 | 1.01T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
232.16 | 560.33B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
223.07 | 401.47B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
119.52 | 298.33B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
181.55 | 288.38B | 60.48B | 10.40B | 8.05B | 3.3297 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-22 | Hochstufung | UBS | Neutral → Buy |
| 2026-04-20 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2026-04-14 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-09 | Bestätigt | H.C. Wainwright | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-10 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2025-11-06 | Hochstufung | Stifel | Hold → Buy |
| 2025-09-25 | Eingeleitet | Jefferies | Buy |
| 2025-07-21 | Fortgesetzt | Truist | Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-04-04 | Herabstufung | Argus | Buy → Hold |
| 2025-02-11 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-01-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-11-18 | Herabstufung | Needham | Buy → Hold |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-14 | Bestätigt | Needham | Buy |
| 2024-02-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-12-20 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-24 | Bestätigt | UBS | Buy |
| 2023-05-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-04-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Hochstufung | Goldman | Neutral → Buy |
| 2022-10-13 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-07 | Hochstufung | Argus | Hold → Buy |
| 2022-09-28 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-28 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Bestätigt | Barclays | Equal Weight |
| 2022-02-04 | Bestätigt | BofA Securities | Neutral |
| 2022-02-04 | Bestätigt | Cowen | Outperform |
| 2022-02-04 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-04 | Bestätigt | Needham | Buy |
| 2022-02-04 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Bestätigt | Robert W. Baird | Neutral |
| 2022-02-04 | Bestätigt | Wedbush | Neutral |
| 2022-02-04 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-02-04 | Bestätigt | Wolfe Research | Peer Perform |
| 2022-01-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-01-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Bestätigt | Truist | Buy |
| 2021-06-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-08 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Bestätigt | Barclays | Equal Weight |
| 2021-06-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-08 | Bestätigt | Jefferies | Buy |
| 2021-06-08 | Bestätigt | Morgan Stanley | Overweight |
| 2021-06-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Stifel | Buy |
| 2021-06-08 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-06-07 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-01-29 | Hochstufung | Stifel | Hold → Buy |
| 2020-11-10 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-11-09 | Herabstufung | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Hochstufung | Jefferies | Hold → Buy |
| 2020-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-07-27 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-04-23 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-27 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Herabstufung | Robert W. Baird | Neutral → Underperform |
Alle ansehen
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Biogen To End Investors' Alzheimer's Drug Case For $18.9M - Law360
Biogen Inc. (BIIB) Faces Securities Fraud Investigation After Cl - GuruFocus
Biogen (BIIB) Upgraded to Buy with Target Price of $255 - GuruFocus
Biogen's Base Is Declining — But 8 Pipeline Readouts Could Flip The Story - Benzinga
Biogen to pay $18.9 million to settle investors' claims over Alzheimer's drug - Reuters
Biogen Inc. stock (US09062X1037): Alzheimer’s portfolio and pipeline in focus after recent updates - AD HOC NEWS
This Biogen Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday - Benzinga
New Progress Toward Public Reimbursement of SKYCLARYS™ for People Living with Friedreich Ataxia in Quebec - BioSpace
BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm - PR Newswire
Needham Upgrades Biogen(BIIB.US) to Buy Rating, Announces Target Price $255 - Moomoo
Needham upgrades Biogen stock rating on pipeline outlook - Investing.com
Biogen (BIIB) Upgraded to Buy with Promising Growth Prospects - GuruFocus
BIIB Upgraded by Needham -- Rating Changed to Buy with Price Tar - GuruFocus
Needham Upgrades Biogen to Buy From Hold, Price Target Is $255 - Moomoo
Assessing Biogen (BIIB) Valuation After Breakthrough Therapy Status And Positive Lupus Trial Data - simplywall.st
Bronstein, Gewirtz & Grossman, LLC Encourages Biogen Inc. (BIIB) Investors to Inquire about Securities Investigation - The National Law Review
Biogen’s Salanersen Win Adds New Dimension To SMA Growth Story - Sahm
Biogen Inc (BIIB) Stock Price, Trades & News - GuruFocus
Biogen faces Italian antitrust probe over rivalry with Sandoz for MS drugs - MSN
Should Biogen’s (BIIB) New SMA Breakthrough and Lupus Data Prompt a Fresh Look From Investors? - Yahoo Finance
A Look At Biogen (BIIB) Valuation After New Breakthrough SMA Nod And Positive Lupus Phase 3 Data - Yahoo Finance
Biogen’s salanersen gets Breakthrough Therapy designation in SMA - The Pharma Letter
BIIB's Next-Gen SMA Therapy Salanersen Wins FDA's Breakthrough Tag - Yahoo Finance
FMR LLC holds 16.65M Biogen shares (BIIB) — 11.3% reported - Stock Titan
Lost Money on Biogen Inc. (BIIB)? Contact The Gross Law Firm Regarding an Ongoing Investigation - GlobeNewswire
FDA names Biogen’s salanersen a breakthrough therapy for SMA - SMA News Today
Key facts: Ionis licenses salanersen to Biogen; sees >$7B peak - TradingView
symbol__ Stock Quote Price and Forecast - CNN
BIIB Stock Price, Quote & Chart | BIOGEN INC (NASDAQ:BIIB) - ChartMill
Biogen (BIIB) Presents Promising Data for Dapirolizumab Pegol at EULAR 2026 - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc.BIIB - PR Newswire
Biogen receives FDA breakthrough designation for SMA therapy - Investing.com
Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy - Biogen
UCB and Biogen build steroid-sparing case for lupus drug - The Pharma Letter
EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce - GlobeNewswire
Biogen Inc (BIIB) Stock Up 3.8% but GF Value Says Overvalued -- GF Score: 75/100 - GuruFocus
Mixed Lupus Win And Parkinson’s Setback Might Change The Case For Investing In Biogen (BIIB) - simplywall.st
Biogen Inc. stock (US09062X1037): Nasdaq shares steady as market digests Alzheimer’s drug outlook - AD HOC NEWS
Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses - The Manila Times
Biogen Showcases Nephrology Advances with EMPAVELI® and Felzartamab at Major Medical Congresses - Quiver Quantitative
Biogen Inc. stock (US09062X1037): shares firm after latest quarterly update and Alzheimer’s portfo - AD HOC NEWS
Biogen Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
On the Edge of Drug Discovery - GW Today
Biogen Ends BIIB122 Parkinsons Trial And Refocuses Neurodegeneration Pipeline - Yahoo Finance
Biogen Inc. stock underperforms Monday when compared to competitors - MarketWatch
Lancet publication adds weight to UCB and Biogen lupus drug case - The Pharma Letter
(BIIB) Risk Channels and Responsive Allocation - Stock Traders Daily
Biogen (BIIB) Unveils Positive Phase 3 Findings for Dapirolizuma - GuruFocus
Biogen, UCB Say Lupus Drug Candidate Meets Primary Endpoint in Phase 3 Trial - marketscreener.com
Biogen Inc. (BIIB) Stock Analysis: A Closer Look At Its 11.96% Upside Potential - DirectorsTalk Interviews
Biogen (BIIB) Drug Trial Achieves Key Endpoint in Lupus Study - GuruFocus
Finanzdaten der Biogen Inc-Aktie (BIIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.61%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):